Mammalian target of rapamycin and head and neck squamous cell carcinoma
- PMID: 21513566
- PMCID: PMC3108931
- DOI: 10.1186/1758-3284-3-22
Mammalian target of rapamycin and head and neck squamous cell carcinoma
Abstract
Head and neck squamous cell carcinoma (HNSCC), a significant cause of cancer deaths worldwide, has multiple stepwise malignant evolutions. Mammalian target of rapamycin (mTOR) plays a critical role in tumor development, invasion, metastasis and angiogenesis that impact local recurrence and survival. mTOR can also act as a biomarker for personalized adjuvant therapy. In in vivo and in vitro studies, mTOR inhibitor suppresses tumor growth and sensitizes HNSCC to radiation, cytotoxic agents and epidermoid growth factor receptor inhibitors. We have reviewed the pathogenesis of HNSCC, mTOR pathway, mTOR inhibitor and the role of mTOR in HNSCC.
Figures
Similar articles
-
MEK Inhibitor PD-0325901 Overcomes Resistance to PI3K/mTOR Inhibitor PF-5212384 and Potentiates Antitumor Effects in Human Head and Neck Squamous Cell Carcinoma.Clin Cancer Res. 2015 Sep 1;21(17):3946-56. doi: 10.1158/1078-0432.CCR-14-3377. Epub 2015 May 14. Clin Cancer Res. 2015. PMID: 25977343 Free PMC article.
-
Epidermal growth factor receptor (EGFR) and squamous cell carcinoma of the skin: molecular bases for EGFR-targeted therapy.Pathol Res Pract. 2011 Jun 15;207(6):337-42. doi: 10.1016/j.prp.2011.03.002. Epub 2011 Apr 29. Pathol Res Pract. 2011. PMID: 21531084 Review.
-
Targeting mTOR-CCL20 Signaling May Improve Response to Docetaxel in Head and Neck Squamous Cell Carcinoma.Int J Mol Sci. 2021 Mar 17;22(6):3046. doi: 10.3390/ijms22063046. Int J Mol Sci. 2021. PMID: 33802643 Free PMC article.
-
Pharmacodynamic evaluation of temsirolimus in patients with newly diagnosed advanced-stage head and neck squamous cell carcinoma.Head Neck. 2010 Dec;32(12):1619-28. doi: 10.1002/hed.21374. Head Neck. 2010. PMID: 20222045 Clinical Trial.
-
Bcl-2 targeted-therapy for the treatment of head and neck squamous cell carcinoma.Recent Pat Anticancer Drug Discov. 2011 Jan;6(1):45-57. doi: 10.2174/157489211793980042. Recent Pat Anticancer Drug Discov. 2011. PMID: 21110823 Review.
Cited by
-
Oncogenic Signalling through Mechanistic Target of Rapamycin (mTOR): A Driver of Metabolic Transformation and Cancer Progression.Cancers (Basel). 2018 Jan 3;10(1):5. doi: 10.3390/cancers10010005. Cancers (Basel). 2018. PMID: 29301334 Free PMC article. Review.
-
Role of Molecular Targeted Therapeutic Drugs in Treatment of Oral Squamous Cell Carcinoma: Development and Current Strategies-A Review Article.Glob Med Genet. 2022 Sep 19;9(3):242-246. doi: 10.1055/s-0042-1756663. eCollection 2022 Sep. Glob Med Genet. 2022. PMID: 36132998 Free PMC article. Review.
-
mTOR Pathway and mTOR Inhibitors in Head and Neck Cancer.ISRN Otolaryngol. 2012 Oct 18;2012:953089. doi: 10.5402/2012/953089. Print 2012. ISRN Otolaryngol. 2012. PMID: 23762622 Free PMC article.
-
Endoplasmic reticulum stress and cell death in mTORC1-overactive cells is induced by nelfinavir and enhanced by chloroquine.Mol Oncol. 2015 Mar;9(3):675-88. doi: 10.1016/j.molonc.2014.11.005. Epub 2014 Nov 22. Mol Oncol. 2015. PMID: 25498902 Free PMC article.
-
mTOR, metabolism, and the immune response in HPV-positive head and neck squamous cell cancer.World J Otorhinolaryngol Head Neck Surg. 2016 Jul 20;2(2):76-83. doi: 10.1016/j.wjorl.2016.05.010. eCollection 2016 Jun. World J Otorhinolaryngol Head Neck Surg. 2016. PMID: 29204551 Free PMC article. Review.
References
-
- Do KA, Johnson MM, Doherty DA, Lee JJ, Wu XF, Dong Q, Hong WK, Khuri FR, Fu KK, Spitz MR. Second primary tumors in patients with upper aerodigestive tract cancers: joint effects of smoking and alcohol (United States) Cancer Causes Control. 2003;14:131–138. doi: 10.1023/A:1023060315781. - DOI - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous